Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Emmanuelle di Tomaso(Bayer (United States)), Dan G. Duda(Harvard University), Onofrio A. Catalano(Harvard University), Jeffrey A. Meyerhardt(CancerCare), Sam S. Yoon(Columbia University Irving Medical Center), Rebecca A. Miksad(Brigham and Women's Hospital), Vivek Sindhwani(Beth Israel Deaconess Medical Center), Pankaj Bhargava(University of North Carolina at Chapel Hill), Johanna Lahdenranta(Harvard University), Thomas A. Abrams(Dana-Farber Cancer Institute), Marek Ancukiewicz(Bridge University), Charles S. Fuchs(University of Southern California), David P. Ryan(East Carolina University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Eunice L. Kwak(Harvard University), Aram F. Hezel(University of Rochester Medical Center), Dushyant V. Sahani(University of Washington)
Cited by 476
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k